Simvastatin

ATC Code C10AA01

Simvastatin

Definition

A lipid-lowering agent derived synthetically from a fermentation product of the fungus Aspergillus terreus. Hydrolyzed in vivo to an active metabolite, simvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)

Also known as [1S-[1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta]]-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2,2-dimethylbutanoate, MK 733, SIMVASTATIN, Synvinolin, Zocor — per NCIT

Also identified as

Indications

Disease Relation Source
Coronary artery disorder may prevent MEDRT · Public domain (U.S. Government work)
Coronary artery disorder may treat MEDRT · Public domain (U.S. Government work)
Hyperlipoproteinemia may treat MEDRT · Public domain (U.S. Government work)
Hypertriglyceridemia may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Cardiovascular system may treat a disease of this organ DERIVED · CC BY 4.0
Heart may treat a disease of this organ DERIVED · CC BY 4.0

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.